London, 01 December 2014 – A new report from research firm TechNavio indicates that unmet treatment requirements have left room for growth in the Global Herpes Market, which is expected to post a CAGR of 10.14 percent from 2014-2018.
The approved antivirals in the market only reduce the frequency of herpes simplex, but do not cure the disease completely. This is providing ample opportunities for investors in the Global Herpes Market.
About the Report
The latest report from TechNavio highlights novel therapies, concentrating on increased safety in combination with increasing patient awareness and compliance. Many promising therapies, especially for Cytomegalovirus (CMV) infections are expected to be launched during the forecast period.
“There are few first-in-class drugs that are undergoing development for the treatment and prevention of herpes viral infections,” says Faisal Ghaus, Vice President of TechNavio.
“The launch of vaccines like GSK1437173A and V212 and pipeline candidates like TransVax are expected to propel this market in the coming years.”
This market currently consists of four primary branded drugs and numerous generic drugs. However, competition in the market is expected to intensify with the presence of numerous small vendors, who are adopting extensive marketing and licensing strategies to gain market share.
Key Information Covered in the Report:
Market segmentation, size and forecast through 2018
Market Growth Drivers:
- Significant Amount of Unmet Need
- For a full detailed list, view our report.
Market Challenges:
- Increased Competition from Generics
- For a full detailed list, view our report.
Market Trends:
- Promising New Launches
- For a full detailed list, view our report.
Key Vendors:
- Gilead Sciences Inc.
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Novartis AG
Other Prominent Vendors:
- Agenus
- AiCuris
- Astellas Pharma
- CytoGenix
https://www.technavio.com/%3Cp%3E%3Ca%20href%3D%22http%3A//www.technavio….
